BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Investor meeting23-11-2022
23-11-2022
Biocon investors await smooth integration, execution of Viatris deal
The Q2 results are not too exciting. While revenue performance was decent, profitability was weaker23-11-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
This is further to our earlier letter dated November 15, 2022 regarding presentation and video recording of Q2 FY23 Earnings Call held on November 15, 2022, please find enclosed herewith the transcript of the Earnings Call. The same is also available on the website of the Company at https://www.biocon.com/investor-relations/financial-information/earning-call-transcripts/. Kindly take the above said information on record.22-11-2022
BIOCON LTD. - 532523 - Disclosure Pursuant To Regulation 30
In reference to the proposed acquisition of biosimilars assets of Viatris Inc., by Biocon Biologics Limited ('BBL'), subsidiary of Biocon Limited, please be informed that BBL and its subsidiaries have executed a Debt Facility Agreement which is classified as a Sustainability-linked Loan (SLL) amounting to US$1.2 billion on November 20, 2022, the proceeds of which shall be used for funding the acquisition of Viatris Inc.'s biosimilars business and acquisition related expenses. We request you to take this on record.21-11-2022
Buy Biocon; target of Rs 340: Sharekhan
Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 340 in its research report dated November 15, 2022.21-11-2022
Buy Biocon; target of Rs 340: Sharekhan
Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 340 in its research report dated November 16, 2022.18-11-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Acquisition
This is with reference to the proposed acquisition of biosimilars assets of Viatris Inc., by Biocon Biologics Limited (BBL), subsidiary of Biocon Limited, please be informed that BBL has allotted equity shares to Biocon Limited* and its affiliate for an amount of Rs. 3,081.99 Crores (~US$ 380 million) and to Serum Institute Life Sciences Private Limited for an amount of Rs. 1,237.49 Crores (~US$ 150 million) on November 16, 2022. *In this regard, requisite disclosure w.r.t. acquisition by Biocon Limited pursuant to Regulation 30 read with Part A of Schedule III of SEBI Listing Regulations is enclosed as Annexure A.17-11-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Credit Rating
We wish to inform you that the Company has received rating letter dated November 17, 2022 from ICRA Limited (ICRA), wherein ICRA has assigned a short-term credit rating of [ICRA]A1+ to the Commercial Paper (to be issued) of Rs. 2,250 crore. The rating letter received in this regard is enclosed as Annexure-A. Further, in respect of Rs. 450 crore bank facilities of the Company, ICRA vide its letter dated November 17, 2022, has decided to continue the long-term rating of [ICRA]AA+ on watch with developing implications, and has removed the short-term rating from watch with developing implications and reaffirmed the short-term rating at [ICRA]A1+. The rating letter received in this regard is enclosed as Annexure-B. The above information will also be available on the website of the Company at www.biocon.com.17-11-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 (6) of the SEBI LODR Regulations, 2015, we hereby inform you that a meeting was conducted with GIC, Singapore, Institutional Investor/ Research Analysts on November 17, 2022. We request you to kindly take the above intimation on record. Thanking You, Yours faithfully, For Biocon Limited17-11-2022
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Intimation of meeting conducted with Institutional Investor/Research Analysts.17-11-2022